A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

This study will evaluate zipalertinib, a novel EGFR tyrosine kinase inhibitor (TKI) versus placebo in participants with resected early stage NSCLC harboring uncommon EGFRmt. Approximately 360 participants will be randomized to: Arm A: Zipalertinib twice daily (BID) monotherapy OR Arm B: Placebo BID monotherapy. An independent data monitoring committee (IDMC) will be established to monitor interim safety data.